Search results
Nanoscope Therapeutics has announced positive results from their two year randomised controlled phase 2b optogenetic therapy trial for late-stage retinitis pigmentosa (RP).
The development of a new treatment is a lengthy process, from early investigation of ideas and principles in the lab, through testing in cell and animal models to the final stages of clinical trials in human patients. The good news is that progress is increasingly rapid.
These frequently asked questions should provide a response for most of the queries you might raise.
Different inherited sight loss conditions present noticeable symptoms at different times.
This session will introduce the technique of optogenetics and its potential for development into a treatment for IRDs.
Our volunteers are highly valued members of the Retina UK team and their roles are essential to help support and enable people affected by inherited sight loss to live fulfilling lives.
Sign up to receive regular updates from Retina UK and learn more about the most innovative research and technology news, upcoming events, fundraising and support services available.
Charles Bonnet syndrome (CBS) causes people who have lost a lot of sight to see things that aren’t real (hallucinations).
As Luxturna reaches the clinic and other gene-specific therapies for inherited retinal disease get closer to the end of the development pipeline, it is becoming ever more important that affected families can access a genetic diagnosis, potentially opening up choices around treatment and clinical trial participation.
Formal notice of the forthcoming Annual General Meeting in June 2023.
